Posted by Michael Wonder on 12 May 2021
BioCryst receives UK approval of Orladeyo (berotralstat), first oral, once daily therapy to prevent attacks in hereditary angioedema patients
12 May 2021 - BioCryst Pharmaceuticals today announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for oral, once-daily Orladeyo (berotralstat) for the routine prevention of recurrent hereditary angioedema attacks in HAE patients 12 years and older.
A decision from the National Institute for Health and Care Excellence and Scottish Medicines Consortium for use of Orladeyo under the UK’s National Health Service is anticipated in the fourth quarter of 2021.
